MedTrace Logo

Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics

NCT02299791 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4856

Last updated 2017-10-04

Study results available
· View outcomes & findings →

Summary

The purpose of the ALL Study is to determine the effectiveness of the dissemination of the ALL intervention from an integrated care setting into Community Health Centers (CHCs) by measuring changes in diabetes mellitus (DM) population prescription rates for the medications, using a pre-post comparison within clinics and a staggered, randomized implementation across clinics.

Conditions

Interventions

OTHER

ALL

This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below. 1. EHR tools to expedite identification a. EHR automated point-of-care alerts (Best Practice Alerts) 2. EHR tools to expedite prescribing 1. EHR order sets 2. EHR text shortcuts for notation 3. patient education materials (handout, poster) 3. EHR-based outreach support tools a. EHR registries

OTHER

ALL

These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • OCHIN, Inc.

    collaborator OTHER

  • Virginia Garcia Memorial Health Center

    collaborator UNKNOWN

  • Multnomah County Health Department

    collaborator OTHER_GOV

  • Oregon Health and Science University

    collaborator OTHER

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Rachel Gold, PhD, MPH · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02299791 on ClinicalTrials.gov